title: Neonatal outcome in a randomized, controlled trial of low-dose aspirin in high-risk pregnancies.
abstract: OBJECTIVE
  To determine the value of low-dose aspirin in high-risk pregnancies, and assess its impact on fetal growth, as well as on perinatal mortality and morbidity.
  
  
  METHODS
  One hundred and eight women with singleton pregnancies were enrolled in a randomized, double-blind, placebo-controlled trial of 100 mg/day aspirin from 17 to 19 week gestation. Enrolment criteria included pre-existing chronic essential hypertension or renal disease, or a history of previous early, severe pre-eclampsia.
  
  
  RESULTS
  There were four stillbirths (all aspirin) and two neonatal deaths (both placebo), to yield respective perinatal mortality rates of 69/1000 and 40/1000 (P = 0.499). Liveborn infants in the aspirin group were significantly more mature (P = 0.017) and of heavier birthweight (P = 0.034) but had similar length (P = 0.091) and head circumference (P = 0.257). Fewer infants in the aspirin group were liveborn prematurely (5/54 vs 14/50; P = 0.016) or were of low birthweight (3/54 vs 9/50; P = 0.052). There were no significant between-group differences for standard deviation (Z) scores for weight, length or head circumference, or for skinfold thickness measurements. There was no significant difference in occurrence of low Apgar scores or in neonatal intensive care unit use between the groups.
  
  
  CONCLUSIONS
  Low-dose aspirin does not appear to have a significant effect on perinatal morbidity. The increase in weight at birth associated with low-dose aspirin therapy is due to prolongation of pregnancy rather than prevention of intra-uterine growth retardation.
authors.affiliation: Department of Neonatology, Royal North Shore Hospital, St Leonards, New South Wales, Australia.
authors.forename: G I
authors.initials: GI
authors.lastname: Leslie
authors.forename: E D
authors.initials: ED
authors.lastname: Gallery
authors.forename: J D
authors.initials: JD
authors.lastname: Arnold
authors.forename: M R
authors.initials: MR
authors.lastname: Ross
authors.forename: A Z
authors.initials: AZ
authors.lastname: Gyory
mesh_terms: D001241:Aspirin / Q000627:therapeutic use*; D002908:Chronic Disease; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D007231:Infant, Newborn; D007674:Kidney Diseases / Q000188:drug therapy*; D008297:Male; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D011225:Pre-Eclampsia / Q000188:drug therapy*; D011247:Pregnancy; D011248:Pregnancy Complications / Q000188:drug therapy*; D011256:Pregnancy Outcome; D018566:Pregnancy, High-Risk / Q000187:drug effects*
chemical_list: D010975:Platelet Aggregation Inhibitors; D001241:Aspirin